Purple Book reference family · 351(a) biologic
efalizumab (Raptiva)
efalizumab is an FDA-licensed reference biologic from Genentech, Inc..
351(a) biologicBLA 125075 Genentech, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2003
Reference product
Originator biologic
351(a)BLA 125075
Raptiva efalizumab
Genentech, Inc.
View full reference-product record- Approved
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Molecular structure
RCSB Protein Data Bank
Experimental 3D structure for efalizumab from the RCSB Protein Data Bank (PDB 3EO9).
Interactive biological assembly from PDB entry 3EO9. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference efalizumab product.
23 yr 3 mo ago
efalizumab: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for efalizumab.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
